Real World Safety & Efficacy Experience of Empagliflozin With or Without Metformin in T2DM Patients - EASE Study

Last updated: February 3, 2023
Sponsor: Getz Pharma
Overall Status: Active - Recruiting

Phase

4

Condition

Diabetes Mellitus, Type 2

Diabetes And Hypertension

Diabetes Prevention

Treatment

N/A

Clinical Study ID

NCT05164263
GTZ-DM-003-21
  • Ages 18-65
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

Study Objective To evaluate the safety and tolerability of Empagliflozin with or without metformin in patients with Type II Diabetes Mellitus in the Pakistani population.

Study design Open-label, prospective, observational, single arm, multi-center, post-marketing surveillance study.

Sample size The estimated sample size will be n=156. Duration of study 12 months (data lock point will be completion of 6 months' follow-up from the time of last patient's enrollment date) Safety Assessment: Patient will be monitored for Hypoglycemia, Dehydration, Hypotension, Urinary Tract Infections, Fungal Infections, Nausea, Vomiting, Diarrhea, Abdominal Discomfort, Flatulence, Asthenia, Indigestion and Other side effects (if any).

Follow up visits: After recruitment, patient is supposed to have three visits for follow-ups.

Visit 1: 4 to 6 weeks of initiation of therapy. Visit 02: At 12 weeks of initiation of therapy. Visit 03: At 24 weeks of initiation of therapy.

LABORATORY TESTING:

Reputable Lab is considered for laboratory testing of diabetes patients i.e. HbA1C%, FBG, RFT and urine R/E. The certified clinical lab will be responsible for receiving and analyzing clinical sample. Patients will have special discount of upto 50% for study related laboratory investigations.

Where in Urine Routine Examination (Urine R/E), we consider as follows:

  • Visual Examination:

    • Urine color: Normal (Yellow), Pale Yellow, Dark Yellow, Brown, Red or Pink or any other.

    • Urine clarity: Clear, slightly Cloudy, cloudy or turbidity

  • Chemical Examination:

    • Specific gravity

    • pH

    • Bilirubin

    • Urobilinogen

    • Protein

    • Ketone

    • Leukocyte Esterase

  • Microscopic Examination:

    • Red Blood Cells:

    • Epithelial Cells:

    • Amorphous:

    • Pus Cells

    • Bacteria

    • Yeast

    • Casts

    • Crystals

Where in Renal Function Test (RFT), we consider as follows:

  • Blood Urea Nitrogen (BUN): mg/dL

  • Serum Creatinine: mg/dL

  • Estimated Glomerular Filtration Rate (eGFR): mL/min/1.73 m2

Eligibility Criteria

Inclusion

Inclusion Criteria: Patient with T2DM between 18 to 65 years with HbA1C 7% - 10%, who can give informedconsent. Patient uncontrolled on oral antidiabetics and lifestyle modification for at least 3 months. Patient who are empagliflozin naive. eGFR ˃60 mL/min/1.73m2.

Exclusion

Exclusion Criteria: Type 1 diabetes, History of recurrent urinary tract infection (UTI), fungal infection,renal and/or hepatic dysfunctions, where RFT and Urine R/E is abnormal, DiabeticKetoacidosis and/or hyperosmolar hyperglycemic state, severe hypoglycemia, Pregnant orlactating women, Pancreatitis, any serious complications or hypersensitivity.

Study Design

Total Participants: 156
Study Start date:
April 01, 2021
Estimated Completion Date:
March 31, 2025

Connect with a study center

  • Umar Diabetes Foundation

    Islamabad,
    Pakistan

    Active - Recruiting

  • NHSL

    Colombo,
    Sri Lanka

    Site Not Available

  • NHK

    Kandy,
    Sri Lanka

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.